Cytokinetics (CYTK) Other Accumulated Expenses (2012 - 2026)
Cytokinetics (CYTK) posted quarterly Other Accumulated Expenses of $8.6 million for Q1 2026, up 47.58% year-over-year from $5.8 million in Q1 2025, and up 124.16% quarter-over-quarter from $3.8 million in Q4 2025.
Cytokinetics (CYTK) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Other Accumulated Expenses for 15 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 47.58% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (up 47.58% YoY), while the FY2025 annual figure was $3.8 million, down 42.13% from the prior year.
- Other Accumulated Expenses advanced to $8.6 million in Q1 2026 per CYTK's latest filing, from $3.8 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $14.8 million in Q1 2024 and bottomed at $2.0 million in Q3 2025.
- Historically, Other Accumulated Expenses has averaged $7.8 million across 5 years, with a median of $6.6 million in 2024.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 666.14% — and 2025, when it sank 64.04%.
- Cytokinetics' Other Accumulated Expenses stood at $6.2 million in 2022, then soared by 69.65% to $10.6 million in 2023, then plunged by 37.27% to $6.6 million in 2024, then slumped by 42.13% to $3.8 million in 2025, then soared by 124.16% to $8.6 million in 2026.
- Business Quant data shows CYTK's Other Accumulated Expenses at $8.6 million in Q1 2026, $3.8 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.36 Mn |
| Mar 31, 2026 | 8.59 Mn |
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 9.59 Mn |
| Mar 31, 2025 | 5.82 Mn |
| Dec 31, 2024 | 6.62 Mn |
| Sep 30, 2024 | 5.53 Mn |
| Jun 30, 2024 | 9.29 Mn |
| Mar 31, 2024 | 14.79 Mn |
| Dec 31, 2023 | 10.56 Mn |
| Sep 30, 2023 | 13.74 Mn |
| Jun 30, 2023 | 6.38 Mn |
| Mar 31, 2023 | 10.71 Mn |
| Dec 31, 2022 | 6.22 Mn |
| Sep 30, 2022 | 5.78 Mn |
| Jun 30, 2022 | 7.69 Mn |
| Mar 31, 2022 | 4.86 Mn |
| Dec 31, 2021 | 5.57 Mn |
| Sep 30, 2021 | 2.41 Mn |